Madrigal Pharmaceuticals, Inc. (MDGL)
Healthcare · NMS · US
Fundamentals
Valuation and ratings
Madrigal Pharmaceuticals, Inc. trades at USD545.53, which is 61% above the USD214.74 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 48 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
MDGL passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Smart money ownership
11 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- John Paulson, PAULSON & CO. INC.$728.77M · 23.4% of book
- Ken Griffin, CITADEL ADVISORS LLC$237.57M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$118.05M · 0.1% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$37.62M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$21.39M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Madrigal Pharmaceuticals, Inc. (MDGL) undervalued?
Against our discounted cash flow estimate of USD214.74, MDGL at USD545.53 is 61% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own MDGL?
11 of the institutions we track reported a position in MDGL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for MDGL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.